Medicines labeled for the same conditions
Alternatives to lebrikizumab
3 other medicines are given the same way (subcutaneous) and in the same FDA class as lebrikizumab or labeled mainly for the same use (eczema (atopic dermatitis)); 1 is in its class, interleukin-13 antagonists: tralokinumab; the others include 1 interleukin-4 receptor alpha antagonist and 1 interleukin-31 receptor alpha antagonist (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as lebrikizumab?
Eczema (atopic dermatitis) lists all 26 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Lebrikizumabinterleukin-13 antagonist | this medicine | none listed | $1,783.52 per mL 250 mg/2 mL pen | No | No current entry |
| Tralokinumabinterleukin-13 antagonist · same class | Eczema (atopic dermatitis) | none listed | n/a | No | No current entry |
| Dupilumabinterleukin-4 receptor alpha antagonist | Eczema (atopic dermatitis) | none listed | $1,773.74 per mL 200 mg/1.14 mL syring | No | No current entry |
| Nemolizumabinterleukin-31 receptor alpha antagonist | Eczema (atopic dermatitis) | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Lebrikizumab: the full record
- label, generics, price, shortages, recalls